Literature DB >> 2432376

Pharmacological receptors for substance P and neurokinins.

D Regoli, G Drapeau, S Dion, P D'Orléans-Juste.   

Abstract

The three neurokinins identified in mammals, substance P, neurokinin A and neurokinin B, as well as their C-terminal biologically active fragments, have been used to characterize the responses of a variety of isolated organs. Three preparations selective either for substance P (the dog carotid artery), or for neurokinin A (the rabbit pulmonary artery) or for neurokinin B (the rat portal vein) are described. A neurokinin receptor classification is attempted using the neurokinins and their fragments to determine the order of potency of agonists. Three receptor subtypes have been identified: the NK-P, on which substance P (SP) is more active than neurokinin A (NKA) and neurokinin B (NKB), and the neurokinins are more active than their respective fragments; the NK-A on which NKA greater than NKB greater than SP, and some NKA fragments are more discriminative than their precursor; the NK-B on which NKB greater than NKA greater than SP, and fragments of NKB are less active than their precursor. Among the peptides studied, some potent compounds have been identified that could provide selective receptor ligands.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2432376     DOI: 10.1016/0024-3205(87)90349-3

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  43 in total

1.  Involvement of tachykinin receptors in sensitisation to cow's milk proteins in guinea pigs.

Authors:  J Gay; J Fioramonti; R Garcia-Villar; X Emonds-Alt; L Bueno
Journal:  Gut       Date:  1999-04       Impact factor: 23.059

2.  Pharmacological specificity of novel, synthetic, cyclic peptides as antagonists at tachykinin receptors.

Authors:  A T McKnight; J J Maguire; N J Elliott; A E Fletcher; A C Foster; R Tridgett; B J Williams; J Longmore; L L Iversen
Journal:  Br J Pharmacol       Date:  1991-10       Impact factor: 8.739

3.  High-Frequency Activation of Nucleus Accumbens D1-MSNs Drives Excitatory Potentiation on D2-MSNs.

Authors:  T Chase Francis; Hideaki Yano; Tyler G Demarest; Hui Shen; Antonello Bonci
Journal:  Neuron       Date:  2019-06-17       Impact factor: 17.173

4.  Inhibition of tachykinin-induced hypotension in dogs by CP-96,345, a selective blocker of NK-1 receptors.

Authors:  J W Constantine; W S Lebel; H A Woody
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-10       Impact factor: 3.000

5.  Bronchoconstrictor and hypotensive effects in relation to pharmacokinetics of tachykinins in the guinea-pig--evidence for extraneuronal cleavage of neuropeptide K to neurokinin A.

Authors:  C R Martling; E Theodorsson-Norheim; I Norheim; J M Lundberg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-08       Impact factor: 3.000

6.  Further evidence for the existence of NK2 tachykinin receptor subtypes.

Authors:  R Patacchini; M Astolfi; L Quartara; P Rovero; A Giachetti; C A Maggi
Journal:  Br J Pharmacol       Date:  1991-09       Impact factor: 8.739

7.  Effects of interactions of naturally-occurring neuropeptides on blood flow in the rat knee joint.

Authors:  F Y Lam; W R Ferrell
Journal:  Br J Pharmacol       Date:  1993-03       Impact factor: 8.739

8.  A non-peptide NK1-receptor antagonist, RP 67580, inhibits neurogenic inflammation postsynaptically.

Authors:  S M Moussaoui; F Montier; A Carruette; J C Blanchard; P M Laduron; C Garret
Journal:  Br J Pharmacol       Date:  1993-05       Impact factor: 8.739

9.  Effects of the tachykinin NK1 receptor antagonist, RP 67580, on central cardiovascular and behavioural effects of substance P, neurokinin A and neurokinin B.

Authors:  J Culman; B Wiegand; H Spitznagel; S Klee; T Unger
Journal:  Br J Pharmacol       Date:  1995-03       Impact factor: 8.739

10.  Involvement of tachykinin receptors in oedema formation and plasma extravasation induced by substance P, neurokinin A, and neurokinin B in mouse ear.

Authors:  H Inoue; N Nagata; Y Koshihara
Journal:  Inflamm Res       Date:  1996-07       Impact factor: 4.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.